Tesamorelin (originally designated TH9507) is a stabilized synthetic analog of growth hormone–releasing hormone (GHRH) that has become one of the most extensively characterized secretagogues in the somatotropic-axis literature. Because it stimulates the pituitary's own pulsatile output of growth hormone rather than replacing the hormone directly, tesamorelin occupies a distinct pharmacological niche among research peptides. This review summarizes the structure, mechanism, and published preclinical and clinical evidence, and situates the compound against related GHRH and ghrelin-mimetic peptides. All content is provided strictly for research reference and is not intended for human or veterinary use.
What is tesamorelin? Tesamorelin is a synthetic 44–amino-acid analog of human GHRH(1–44), modified with a trans-3-hexenoyl group on its N-terminal tyrosine. That modification resists enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4), so the peptide engages pituitary GHRH receptors long enough to stimulate endogenous, pulsatile growth-hormone release and a downstream rise in insulin-like growth factor 1 (IGF-1) [1,3].
Introduction
Native GHRH is a hypothalamic peptide that drives the anterior pituitary to secrete growth hormone (GH) in discrete pulses. Its usefulness as a research tool has always been constrained by an extremely short circulating life — native GHRH(1–44) is cleaved within minutes at its N-terminus by DPP-4 [3,6]. Tesamorelin was engineered specifically to overcome that liability while preserving the physiological pattern of GH release. As a result, it has been studied not as a hormone substitute but as a probe of the GHRH–GH–IGF-1 axis under conditions where the pituitary's secretory machinery and its negative-feedback controls remain intact [2,6].
The compound is best known in the clinical literature for its investigation in HIV-associated visceral adiposity, where it holds a regulatory approval, but the broader research interest spans hepatic-fat metabolism, glucose homeostasis, and neuroendocrine questions about IGF-1 signaling in the aging brain [1,4,5]. This review treats each of those domains in turn and then compares tesamorelin with the ghrelin-mimetic and GHRH-analog peptides most often discussed alongside it.
The somatotropic axis
Growth-hormone secretion is governed by two opposing hypothalamic signals: GHRH, which is stimulatory, and somatostatin, which is inhibitory. Superimposed on these is ghrelin, an endogenous ligand of the growth-hormone secretagogue receptor (GHS-R) that amplifies GH pulses through a separate pathway. GH released into the circulation acts on hepatocytes and peripheral tissues to generate IGF-1, the principal mediator of the axis's anabolic and metabolic effects [2,4].
Two features of this system are central to understanding tesamorelin. First, the axis is pulsatile — GH is released in bursts rather than continuously, and the pattern itself carries biological information distinct from total exposure. Second, it is feedback-regulated — rising IGF-1 and GH restrain further secretion through somatostatin and direct pituitary feedback. Exogenous recombinant GH bypasses both features, delivering continuous, non-physiological hormone levels. A secretagogue such as tesamorelin, by contrast, works upstream and therefore leaves the pulsatility and feedback architecture in place, which is precisely why it is valued as a research instrument for studying the axis [2,3,6].
Structure and mechanism of action
Tesamorelin is a full-length 44–amino-acid peptide corresponding to human GHRH(1–44), distinguished from the parent molecule by a single N-terminal modification: a trans-3-hexenoyl (hexenoic acid) group attached to Tyr1 [3,6]. This acyl cap acts as a steric shield, hindering DPP-4 access to the peptide backbone and extending the functional half-life from the mere minutes of native GHRH to roughly 26–38 minutes [3]. The distinction is important in research contexts — tesamorelin is a stabilized analog of the full-length releasing hormone, not a truncated fragment, and it retains the complete receptor-binding sequence of GHRH.
Mechanistically, tesamorelin behaves as a GHRH-receptor agonist. The GHRH receptor is a Gs-coupled class B G-protein-coupled receptor expressed on pituitary somatotrophs. Receptor engagement activates adenylate cyclase, raising intracellular cyclic AMP, which in turn activates protein kinase A, mobilizes calcium, and triggers exocytosis of stored GH secretory granules [3,6]. Because the stimulus acts through the native receptor, the resulting GH output remains pulsatile and subject to somatostatin and IGF-1 feedback — the mechanistic signature that separates a secretagogue from direct hormone administration [2,3].
Evidence by research domain
The published evidence base for tesamorelin is unusually mature for a research peptide, anchored by several randomized, double-blind, placebo-controlled trials. The table below summarizes the principal domains, the models in which they have been examined, the reported observations, and the maturity of the evidence.
| Research domain | Typical models | Reported findings | Evidence maturity |
|---|---|---|---|
| Visceral adipose tissue | Randomized clinical trials (HIV-associated lipodystrophy) | Selective reduction of visceral fat with minimal change in subcutaneous fat [1,7] | High — multiple phase 3 RCTs |
| Hepatic fat / NAFLD | RCT in HIV-associated NAFLD; MR spectroscopy | ~37% relative reduction in hepatic fat fraction; less fibrosis progression [4] | Moderate — single well-designed RCT |
| Lipid metabolism | Clinical trial secondary endpoints | Lower triglycerides, improved cholesterol/HDL ratio [1,7] | Moderate–high |
| Cognition / neuroendocrine | RCT in older adults with and without MCI | Favorable effect on executive function; verbal-memory trend [5] | Preliminary — single RCT |
| Glucose homeostasis | Clinical trial safety endpoints | No clinically meaningful change in fasting glucose/HbA1c in studied groups [1,7] | Moderate |
Visceral adipose tissue
The most robust body of evidence concerns visceral adipose tissue (VAT). In the registrational program — a randomized, double-blind, placebo-controlled trial reported by Falutz and colleagues in the New England Journal of Medicine and subsequent pooled analyses — tesamorelin was associated with a roughly 15% reduction in VAT relative to placebo over 26 weeks, with a corresponding rise in IGF-1 and improved triglycerides, while subcutaneous fat was largely preserved [1,7]. Pooled data across 806 participants reproduced a treatment effect of approximately 15% [7]. A consistent observation across these studies is that the effect is reversible: discontinuation was followed by a return of VAT toward baseline, underscoring that the compound modulates an ongoing process rather than producing a durable structural change [7].
Hepatic fat and NAFLD
A separate randomized trial by Stanley and colleagues in The Lancet HIV examined hepatic fat in participants with HIV-associated non-alcoholic fatty liver disease, using proton MR spectroscopy to quantify liver-fat fraction. The tesamorelin arm showed an absolute reduction in hepatic fat fraction of about 4 percentage points (a ~37% relative reduction), a higher rate of steatosis resolution, and a lower rate of fibrosis progression than placebo [4]. The proposed mechanism is GH-driven hepatic beta-oxidation of fat. Importantly, the compound did not reverse established fibrosis, and the data are confined to an HIV-positive population — extrapolation to the general NAFLD population is not supported by comparable trials [4].
Cognition and neuroendocrine signaling
Interest in IGF-1 signaling in the brain motivated a randomized, placebo-controlled trial by Baker and colleagues in older adults, including participants with mild cognitive impairment. Over 20 weeks the tesamorelin arm showed a favorable overall effect on cognition driven chiefly by executive-function measures, with verbal memory showing only a trend [5]. The authors linked the finding to the presence of IGF-1 receptors in the hippocampus and prefrontal cortex and to a substantial rise in circulating IGF-1. This remains a single, preliminary trial, and the relative contribution of direct neural effects versus systemic metabolic change is unresolved [5].
Tesamorelin vs. other GH secretagogues
Because tesamorelin is frequently discussed alongside other GH-axis peptides, a mechanistic comparison clarifies where it fits. The critical distinction is GHRH analogs (which act at the GHRH receptor) versus ghrelin mimetics / GHRPs (which act at the separate GHS-R). Tesamorelin, CJC-1295, and sermorelin are all GHRH-receptor agonists; ipamorelin and GHRP-6 act through the ghrelin receptor.
| Compound | Class / receptor | Structural note | Distinguishing research feature |
|---|---|---|---|
| Tesamorelin | GHRH analog (GHRH-R) | Full GHRH(1–44) + trans-3-hexenoyl cap | Most mature clinical dataset; visceral-fat and hepatic-fat literature [1,4] |
| Sermorelin | GHRH analog (GHRH-R) | Truncated GHRH(1–29) fragment | Shortest-acting; historically a diagnostic GHRH probe |
| CJC-1295 | GHRH analog (GHRH-R) | GHRH(1–29) with stabilizing substitutions | Longer receptor engagement than sermorelin |
| Ipamorelin | GHRP / ghrelin mimetic (GHS-R) | Pentapeptide | Highly selective; minimal cortisol/prolactin effect in studies |
| GHRP-6 | GHRP / ghrelin mimetic (GHS-R) | Hexapeptide | Pronounced appetite signaling via ghrelin pathway |
Tesamorelin vs. ipamorelin
These two peptides are often compared because both raise GH, but they engage entirely different receptors. Tesamorelin is a GHRH-receptor agonist acting on the same pathway as endogenous GHRH, whereas ipamorelin is a selective ghrelin-receptor agonist [2,6]. In research designs the two are sometimes examined together precisely because GHRH and ghrelin-pathway stimulation are reported to be synergistic on GH pulse amplitude. Tesamorelin carries by far the larger body of controlled clinical evidence, while ipamorelin is characterized largely in shorter pharmacodynamic and preclinical studies.
Tesamorelin vs. CJC-1295 and sermorelin
All three are GHRH-receptor agonists, so the meaningful distinctions are structural and pharmacokinetic. Sermorelin is a truncated GHRH(1–29) fragment retaining the minimal active sequence; CJC-1295 is that fragment with substitutions that extend receptor engagement; tesamorelin is the full-length GHRH(1–44) sequence with an N-terminal acyl cap conferring DPP-4 resistance [3,6]. This fragment-versus-full-length distinction is central to interpreting the literature: tesamorelin's stability arises from a protective modification of the complete releasing-hormone sequence rather than from truncation, and it is the only member of the group with a mature phase-3 clinical dataset [1,7].
Limitations and research considerations
Population specificity. The strongest evidence — VAT reduction and hepatic-fat effects — derives from HIV-positive study populations. Whether these observations generalize to other contexts has not been established in comparably powered trials [4,7].
Reversibility. Reported metabolic effects diminished after discontinuation, indicating that the compound modulates a dynamic process rather than inducing a lasting change [7].
IGF-1 elevation. Because the mechanism raises IGF-1, the safety literature emphasizes monitoring of IGF-1 in clinical settings and notes a theoretical contraindication in the presence of active malignancy [6]. These are reasons for caution when interpreting research findings, not use guidance.
Single-trial domains. The cognition and NAFLD signals each rest on one well-designed trial; replication is needed before firm conclusions [4,5].
Where to source for research
Reproducible peptide research depends on well-characterized, analytically verified material accompanied by certificates of analysis and mass-spectrometry / HPLC purity documentation. Among suppliers that catalog GHRH-analog reference compounds for laboratory use, Short Chain Aminos is a commonly referenced source that publishes third-party analytical data. Additional suppliers maintaining research-use catalogs in this class include BioPep, Catalyst Research, and Apex Research Services. As with any research material, laboratories should independently confirm identity, purity, and handling documentation rather than relying on catalog descriptions alone. For guidance on evaluating vendors, see our guide to evaluating research peptide suppliers.
Frequently asked research questions
What is tesamorelin used for in research?
In the literature it is studied as a probe of the GHRH–GH–IGF-1 axis, with the most developed datasets addressing visceral adipose tissue, hepatic fat, lipid metabolism, and preliminary neuroendocrine questions. All such work is research-use-only and is not a basis for human or veterinary application [1,4,5].
How does tesamorelin differ from recombinant growth hormone?
Recombinant GH delivers continuous, non-physiological hormone directly. Tesamorelin instead stimulates the pituitary to release its own GH in pulses, so endogenous negative-feedback and pulsatility are preserved. This upstream, secretagogue mechanism is the main reason it is used to study the axis rather than to replace the hormone [2,3].
Is tesamorelin a peptide fragment or a full-length analog?
It is a full-length analog of GHRH(1–44), not a truncated fragment like sermorelin's GHRH(1–29). Its stability comes from a trans-3-hexenoyl group on the N-terminal tyrosine that blocks DPP-4 cleavage while retaining the complete GHRH sequence [3,6].
How does tesamorelin compare with ipamorelin?
They act on different receptors: tesamorelin on the GHRH receptor and ipamorelin on the ghrelin (GHS) receptor. Both raise GH, and the two pathways are reported to be synergistic. Tesamorelin has a far larger controlled clinical evidence base, while ipamorelin is characterized mainly in shorter pharmacodynamic studies [2,6].
What does the evidence show about liver fat?
A randomized trial in HIV-associated NAFLD reported roughly a 37% relative reduction in hepatic fat fraction and less fibrosis progression versus placebo, attributed to GH-driven hepatic fat oxidation. The compound did not reverse established fibrosis, and findings are limited to an HIV-positive population [4].
Why is IGF-1 monitoring emphasized in the literature?
Because the mechanism elevates IGF-1, published safety discussion stresses tracking IGF-1 and notes a theoretical contraindication with active malignancy. In a research context this is a data-interpretation and handling consideration, not administration guidance [6].
Works Cited
- Falutz J, et al. "Metabolic effects of a growth hormone–releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359–2370. PMID: 18057338. DOI: 10.1056/NEJMoa072375.
- Sackmann-Sala L, Kopchick JJ, et al. Reviews of the GHRH–GH–IGF-1 axis and secretagogue pharmacology. StatPearls / NCBI Bookshelf, NBK548730.
- Ferdinandi ES, et al. Structural and pharmacokinetic characterization of tesamorelin (TH9507), a stabilized GHRH(1–44) analog. Pharmacology reviews summarized in NBK548730 and peptide research profiles.
- Stanley TL, et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV." The Lancet HIV. 2019;6(12):e821–e830. PMID: 31611038. DOI: 10.1016/S2352-3018(19)30338-8.
- Baker LD, et al. "Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults." Archives of Neurology. 2012;69(11):1420–1429. DOI: 10.1001/archneurol.2012.1970.
- Stanley TL, Grinspoon SK. Tesamorelin mechanism and GHRH-receptor pharmacology. NCBI Bookshelf NBK548730 and associated reviews.
- Falutz J, et al. "Effects of tesamorelin on visceral fat and metabolic parameters: pooled phase 3 analysis." Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304. PMID: 20554713. (See also PMID: 22495074; PMID: 20101189.)
Research Use Only. The information above summarizes published preclinical and clinical literature for laboratory reference. It is not medical advice and does not describe or endorse any human or veterinary use, dosing, or administration. Tesamorelin and related compounds discussed here are intended solely for in-vitro and research applications.
Explore related compounds: CJC-1295 · Ipamorelin · GHRP-6